63 results about "Microbial biomarkers" patented technology

The invention discloses a mental disorder related intestinal tract microbial marker and application thereof. The intestinal tract microbial marker refers to one or more combinations of intestinal tract microbial florae of Prevotella and Bacteroides. The invention further discloses application of the mental disorder related intestinal tract microbial marker in preparing reagents for diagnosing mental disorders and methods for screening food, probiotics or drugs capable of intervening with mental disorders. Particularly, the methods include comparing proportion of microbial florae of Prevotella to microbial florae of Bacteroides before and after treatment or interference of the food, probiotics or drugs and/or comparing relative quantity of microbial florae of Prevotella and microbial florae of Bacteroides in feces specimens.

The invention discloses a microbial marker of liver cirrhosis, and an application. The microbial marker is one or more selected from one microorganism of Veillonella atypica ACS-134-V-Col7a enriched in a patient group suffering the liver cirrhosis or two microorganisms of Bacteroides uniformis ATCC8492 and Clostridiales enriched in a healthy group. The invention also relates to a drug for treating the liver cirrhosis. A drug for treating the liver cirrhosis can promote or increase one or two selected from the two microorganisms of Bacteroides uniformis ATCC8492 and Clostridiales enriched in the healthy group, and/or suppress or clear the microorganism of Veillonella atypica ACS-134-V-Col7a enriched in the patient group suffering the liver cirrhosis. The method detects relative abundance of the microbial marker in intestinal flora and compares the obtained relative abundance value and a predetermined cutoff value. The invention also relates to a beneficial microorganism combination or functional food. The beneficial microorganism combination or functional food comprises one or two of the two microorganisms of Bacteroides uniformis ATCC8492 and Clostridiales enriched in the healthy group. The invention also relates to a kit for detecting the liver cirrhosis, monitoring a treatment process, or producing and screening the drug. The kit is used for detecting the microbial marker.

The present invention relates to the field of medicine and in particular to celiac disease (CD). Specifically the present invention relates to methods and means for detection of CD using novel microbiomarker, celiac gut index (CGI). The invention relates also to methods and means for treatment or prophylaxis of CD. The present invention provides a novel product comprising a gut microbiome altering agent that, when administered to an individual, improves the state of health of individuals suffering or susceptible to suffer from celiac disease and possibly reduces the likelihood of acquiring celiac disease. The product of the invention provides a natural and safe manner for the treatment of celiac disease. The present invention provides also a novel method for aiding diagnosis of CD by the specific gut health biomarker, Celiac Gut Index (GCI). In the method a probability of a subject having celiac disease is determined by measuring the relative abundances of one or more microbial taxa in a fecal sample from a subject; and the probability of the subject having CD is determined based on the measured abundances as celiac gut index (CGI).

The invention provides a microbial marker of type II diabetes mellitus and an application of the microbial marker. The microbial marker comprises a composition of Eggerthella, Erysipelotrichaceae, Faecalitalea, Lachnospiraceae_ge and Lachnoclostridium. The microbial marker of the type II diabetes millitus has a high correlation with the type II diabetes millitus, can be used to assist in the diagnosis or early warning of the risk of the type II diabetes mellitus, and is also beneficial for individuals to improve the microenvironment of intestinal bacterial by adjusting diet or medical interference, thereby reducing the risk of developing the type II diabetes mellitus.

The invention discloses an ankylosing spondylitis microbial marker, which is formed by the following microbes: Actinomyces sp. ICM47, Bifidobacterium breve, Bifidobacterium sp.12_1_47 BFAA, Bifidobacterium longum, Collinsella aerofaciens, Bifidobacterium bifidum and Bifidobacterium pseudocatenulatum. The invention also discloses a method and a device for determining an individual condition by utilizing the ankylosing spondylitis microbial marker. Compared with a healthy group, the ankylosing spondylitis microbial marker is obviously enriched in an ankylosing spondylitis patient population, and can be used as a distinction marker of the healthy population and the ankylosing spondylitis patient population.

The disclosure provides methods for rapid fractionation of circulating RNAs based on the type of carriers they locate in. The disclosure further provides that the methods of the disclosure can be used for diagnosing a disorder in a subject by identifying specific microRNA biomarkers associated with that disorder.

The invention belongs to the technical field of microorganisms, and particularly relates to a diarrhea-type irritable bowel syndrome intestinal microbial marker and application thereof. The enteric microbe marker comprises a Staphyloccus genus, an Akkermansia genus, an Enterobacter genus, a Dubosiella genus and a Lactobacillus genus. The level change of intestinal flora in mice with diarrhea-type irritable bowel syndrome diseases is discovered for the first time, early diagnosis of diarrhea-type irritable bowel syndrome is realized, and the kit has the advantages of high specificity, high sensitivity, simplicity in collection and treatment of detection objects, no invasion, low cost and the like; and the discovery of the marker provides reference for diagnosing the microbial diarrhea-type irritable bowel syndrome.

The invention discloses a microbial flora marker for evaluating the chemotherapy curative effect of pancreatic cancer and an application of the microbial flora marker, belongs to the technical field of medical detection. By obtaining the relative abundance content of the microbial marker and giving a prediction probability through model calculation, the microbial flora marker can be used for assisting in evaluating the chemotherapy curative effect of pancreatic cancer, reducing an improper chemotherapy cycle and buying time for effective treatment of a patient.

The invention relates to application of alloprevotella in identifying and/or distinguishing individuals of different races. The application of a microbial marker in identifying and/or distinguishing the individuals of different races is provided, and the microbial marker is alloprevotella.

The invention discloses a myasthenia gravis diagnostic reagent kit taking microorganisms as diagnostic markers and an application. The reagent kit comprises a reagent capable of detecting the microbial markers, and the microorganisms are Prevotella_stercorea or a combination of the Prevotella_stercorea and Sutterella_parvirubra. The myasthenia gravis can be predicted, and a rapid diagnostic reagent for preventing and diagnosing myasthenia gravis is developed.

The invention relates to an application of intestinal flora in nerve injury detection. The intestinal flora is pseudomonas aeruginosa, veillonella and streptococcus digestive. According to the invention, the horizontal change of the specific flora in nerve injury is firstly discovered, the nerve injury diagnosis can be achieved by detecting the change of the specific flora, and with the application of the microbial marker to diagnose, the operation is simple, the specificity is high, and the sensitivity is strong.

The invention discloses a microbial marker for bovine endometritis. The microbial marker comprises the following microorganisms with remarkably increased abundance: Bacteriodetes, Elusimicrobia, Verrucomicrobia, Spirochaetae and Lentisphaerae. The microbial marker also comprises the following microorganisms with remarkably increased abundance: Akkermansia, biogas bacillus, CF231 and Oscillosporia.The microbial marker also comprises the following microorganisms with remarkably decreased abundance: Ureaplasma urealyticum, Butyrivibrio, Doria, Sphingomonas sp, Rothia and Streptococcus. The invention discloses an application of the microbial marker for bovine endometritis in preparation of a tool for early screening or prediction of bovine endometritis. The applicant performs 16S rRNA gene sequencing on microbial DNA of a uterine mucus sample, compares structural differences of uterine florae between healthy and sick dairy cows, and finds differences in microbial community composition ofthe uterine florae between the healthy and sick dairy cows. The result provides a theoretical basis for better prevention and treatment of clinical endometritis.

The invention discloses an intestinal metagenomic feature used as a fecal microbiota transplantation curative effect screening marker for type 2 diabetes mellitus patients. The intestinal microbe metagenomic feature is Rinkenellaceae family and Anerotrunk family intestinal flora, and the type 2 diabetes mellitus patient suitable for fecal microbiota transplantation treatment are selected according to the expression levels of the specific intestinal flora markers. Corresponding detection kits are designed and developed according to the intestinal flora biomarkers and different detection technology platforms. The system and the product can be used for precise treatment of type 2 diabetes mellitus based on individualization.